Dear investors and prospects,
Thank you for your investment and interest to date. We have news Moni and I are excited to share about our progress towards FDA Clearance, CE Mark and financing.
FDA CE November Progress Report
From: FreMon Scientific, Inc (FMS) – Fred Thacher, CEO
Subject: Recent FDA, CE Mark, Production Engineering and Finance Activities
Date: November 15, 2017, by Fred Thacher FMS CEO and Co-Founder
Last week: Moni and I met in Israel with the FDA/CE Mark agent Qsite and with Mintz Levin FDA attorney to review production engineering requirements for compliance.
FMS at the AABB 2017 in San Diego
Moni and Fred attended the annual American Association of Blood Banks (AABB) meeting in San Diego the other week. Blood banks, transfusion centers, hospitals, laboratories, pharmaceutical companies and medical device manufacturers from across the globe were present.
FreMon Scientific Completes 1st Round Financing
FreMon Scientific has successfully completed a first round financing resulting in a working prototype blood, plasma and tissue warming and thawing device.
(more…)
New York Blood Center Completes ZipThaw202™ and ZipSleeve™ Testing
The New York Blood Center (NYBC) trial group completed testing FreMon Scientific’s new blood, plasma and tissue products warming and thawing device and disposable: ZipThaw202™ and ZipSleeve™. (more…)
FreMon Scientific Accepts ZipThaw202™ From Sysmop Technologies
FreMon Scientific accepted final delivery of the ZipThaw202™ prototype from Sysmop Technologies of Israel at the New York Blood Center on August 17th 2017.
(more…)